This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated With Reintubation In Premature Infants

WARRINGTON, Pa., May 1, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN ®, when compared with infants treated with Curosurf ® and Survanta ®, the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants.  The analysis, which is expected to appear in publication later this year, was presented at the 2012 Pediatric Academies Society Annual Conference ( April 28May 1, 2012) in Boston, MA.

"This analysis suggests that the selection of a specific surfactant can significantly impact hospital costs based on the rate of reintubation observed with each therapy," said Dr. Russell G. Clayton, Senior Vice President, Research & Development, of Discovery Labs.  "In this pharmacoeconomic model, the lower rate of reintubation observed in infants receiving SURFAXIN also resulted in a potential reduction in healthcare resource utilization and per-patient hospital cost when compared to treatment with today's market leading animal-derived surfactants."

The current standard of care for respiratory distress syndrome (RDS) typically requires that the infant undergo intubation (insertion of a breathing tube into the infant's airway) to allow for surfactant administration and respiratory support via mechanical ventilation.  If therapy is successful, the breathing tube is removed to allow the infant to breathe independently.  However, over one third of infants have difficulty breathing independently after the breathing tube is removed and require reintubation. 

Retrospective analysis of data from Discovery Labs' two large phase 3 trials involving a total of 1546 patients shows that the reintubation rate in SURFAXIN-treated infants ranged from 33 to 35 percent and was significantly lower ( p < 0.05) compared with treatment with Curosurf (47 percent), the current global market leader, and Survanta (43 percent).  These data were previously published in the Journal of Neonatal- Perinatal Medicine (Volume 4, Number 2, 2011) in a manuscript entitled "Reintubation and risk of morbidity and mortality in preterm infants after surfactant replacement therapy" (Guardia et al.).  Based on these data, pharmacoeconomic modeling reveals that the higher rates of reintubation observed with the use of Curosurf and Survanta also results in potential increases in direct hospital costs related to the need for extended mechanical ventilation and the daily cost of care for these infants.  Although the retrospective analysis also demonstrates that reintubation results in an increase in morbidities, such as bronchopulmonary dysplasia and air leak, the pharmacoeconomic modeling does not include the additional costs associated with these morbidities.  The study authors noted that additional pharmacoeconomic analyses of potential reduction in reintubation-associated morbidities are warranted.

Dr. Clayton continued, "Analysis of our phase 3 data has already demonstrated that reintubation appears to be related to higher mortality as well as increases in key morbidities.  These observations, along with the results of this pharmacoeconomic analysis, represent important information for neonatal health care providers to consider when choosing a surfactant for their patients."

Stock quotes in this article: DSCO 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs